Plain-English translation of NCT07735624 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two new immunotherapy drugs called and in people with early-stage rectal cancer. The study wants to see if this medication combination can shrink tumors before surgery, and whether some patients might be able to avoid surgery altogether or have a less invasive procedure instead. Researchers will carefully monitor how well the treatment works and how safe it is.
Currently, most people with early rectal cancer need surgery to remove the tumor, and some also need chemotherapy or radiation. This trial exists because doctors hope this new medication approach might work well enough to let some patients skip traditional surgery or have a smaller, less invasive procedure instead, which could mean better quality of life.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would receive the medication as IV infusions (through an IV line in your arm) over about 30 minutes each. You would get one dose of the first drug on day 1, then receive the second drug every 2 weeks for up to 6 months. During this time, doctors will monitor your tumor with imaging scans and check your health regularly. After 6 months, your doctor will assess how well the treatment worked โ if your tumor has shrunk significantly or gone away, you may be able to have a smaller surgery or close monitoring instead; if there is still disease present, you would proceed with standard surgery as planned.
AI-generated summary from trial data ยท Nov 17, 2026 ยท Not medical advice
United States